Syros to Present at Sidoti June 2023 Virtual Small-Cap Conference
08 Giugno 2023 - 1:30PM
Business Wire
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company
committed to advancing new standards of care for the frontline
treatment of hematologic malignancies, today announced that its
Chief Executive Officer, Nancy Simonian, M.D., will present a
corporate overview at the Sidoti June 2023 Virtual Small-Cap
Conference. Management will also be available for one-on-one
meetings. Details are as follows:
Sidoti June 2023 Virtual Small-Cap Conference
Date: Thursday, June 15 Time: 10:00 a.m. ET
A live webcast of the presentation will be available on the
Investors & Media section of the Syros website at
www.syros.com. An archived replay of the webcast will be available
for approximately 30 days following the presentation.
About Syros Pharmaceuticals
Syros is committed to developing new standards of care for the
frontline treatment of patients with hematologic malignancies.
Driven by the motivation to help patients with blood disorders that
have largely eluded other targeted approaches, Syros is advancing a
robust late-stage clinical pipeline, including tamibarotene, an
oral selective RARα agonist in patients with higher-risk
myelodysplastic syndrome and acute myeloid leukemia with RARA gene
overexpression, and SY-2101, a novel oral form of arsenic trioxide
in patients with acute promyelocytic leukemia. Syros is also
seeking partnerships for SY-5609, a highly selective and potent
CDK7 inhibitor in clinical development for the treatment of select
solid tumors, and multiple preclinical programs in oncology. For
more information, visit www.syros.com and follow us on Twitter
(@SyrosPharma) and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230608005068/en/
Syros Karen Hunady Director of Corporate Communications
& Investor Relations 1-857-327-7321 khunady@syros.com
Media Brittany Leigh, Ph.D. LifeSci Communications, LLC
+1-813-767-7801 bleigh@lifescicomms.com
Investor Hannah Deresiewicz Stern Investor Relations,
Inc. 212-362-1200 hannah.deresiewicz@sternir.com
Grafico Azioni Syros Pharmaceuticals (NASDAQ:SYRS)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Syros Pharmaceuticals (NASDAQ:SYRS)
Storico
Da Giu 2023 a Giu 2024
